Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

PMS2 (PMS1 protein homolog 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

PMS2 mutation	Gastric Cancer	PMS2 mutation	Gastric Cancer	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2
PMS2 mutation	Gastric Cancer	PMS2 mutation	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Colorectal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MSI-H/dMMR + PMS2 deletion	Colorectal Cancer	MSI-H/dMMR + PMS2 deletion	Colorectal Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PMS2 mutation	Melanoma	PMS2 mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MLH1 deletion+ PMS2 deletion	Endometrial Cancer	MLH1 deletion+ PMS2 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
PMS2 mutation + MLH1 mutation	Gastric Cancer	PMS2 mutation + MLH1 mutation	Gastric Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PMS2 mutation + MLH1 mutation	Colorectal Cancer	PMS2 mutation + MLH1 mutation	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MLH1 deletion+ PMS2 deletion	Rectal Cancer	MLH1 deletion+ PMS2 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma	MSI-H/dMMR + MLH1 deletion + PMS2 deletion	Esophageal Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
PMS2 negative	Colon Cancer	PMS2 negative	Colon Cancer	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4	nivolumab + ipilimumab Sensitive: C4 – Case Studies nivolumab + ipilimumab Sensitive : C4
PMS2 1144+1G>A	Lung Adenocarcinoma	PMS2 1144+1G>A	Lung Adenocarcinoma	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4